IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, Matsumoto H, Matsuura H, Matsubara T, Shimizu K, Ogura H, Matsuura Y, Kishimoto T. · 2020
Read IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. by Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, Matsumoto H, Matsuura H, Matsubara T, Shimizu K, Ogura H, Matsuura Y, Kishimoto T. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7486751.txt.
Description
Kang and co-authors trace how IL-6 signaling drives a clotting factor in cytokine release syndrome. This syndrome is a life-threatening surge of inflammation. No targeted immune therapy existed for it.
In patients with sepsis, lung failure syndrome, and burns, IL-6 drove output of inflammatory cytokines and of plasminogen activator inhibitor-1, or PAI-1. The signal ran through vessel lining cells by the trans-signaling route. PAI-1 blocks clot breakdown, so its rise links inflammation to clotting risk. Blocking IL-6 signaling with tocilizumab lowered PAI-1 output. It also eased symptoms in severe COVID-19 patients in this work. The authors mark IL-6 blockade as a candidate therapy. The path may serve several hyperinflammatory states at once.
Catalog record
| CREATOR | Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, Matsumoto H, Matsuura H, Matsubara T, Shimizu K, Ogura H, Matsuura Y, Kishimoto T. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |